Projecting future drug expenditures--2001

Area of Science:

• Health Economics
• Pharmaceutical Policy

Background:

• The year 2000 presented new challenges in drug pricing, therapy, distribution, and overall costs.
• Pharmaceutical expenditures represent a growing portion of total healthcare spending.

Purpose of the Study:

• To project drug costs for 2001 and identify key influencing factors.
• To analyze trends in drug development, generic drug market growth, and regulatory changes impacting pharmaceutical spending.

Main Methods:

• Analysis of drug cost trends and projections for 2001.
• Review of research and development expenditures and new drug approvals.
• Examination of the generic drug market expansion and prescription to nonprescription drug conversions.

Main Results:

• Anticipated drug cost increase of 11-15% in 2001.
• Significant growth in research and development (R&D) expenditures without a proportional increase in new drug approvals.
• Projected rise in generic drug sales to $20 billion by 2005 and total drug sales to $243 billion by 2008, representing 12.6% of healthcare spending.

Conclusions:

• Drug costs are expected to continue double-digit growth in 2001, driven by utilization, new product introductions, and price hikes.
• Emerging factors like new distribution systems, federal pricing initiatives, drug imports, and state-level cost-reduction efforts will shape the pharmaceutical market.
• The conversion of prescription drugs to nonprescription status may offer some budget relief.